Skip to main content
Glenmark Pharmaceuticals ltd logo

Glenmark Pharmaceuticals ltd — Investor Relations & Filings

Ticker · GLENMARK ISIN · INE935A01035 LEI · 335800WKECZXIIT9GK20 BSE.NS Manufacturing
Open in API
Filings indexed 1,033 across all filing types
Latest filing 2026-03-20 Regulatory Filings
Country IN India
Listing BSE.NS GLENMARK

About Glenmark Pharmaceuticals ltd

https://glenmarkpharma.com/

Glenmark Pharmaceuticals Ltd. is a research-driven global organization focused on the development, manufacturing, and marketing of generic, specialty, and over-the-counter medicines. The company maintains a specialized focus on therapeutic areas including dermatology, respiratory health, and oncology. It operates a robust research and development pipeline featuring New Chemical Entities (NCEs) and New Biological Entities (NBEs), supported by multiple global R&D centers. Its commercial footprint extends across North America, Europe, and emerging markets. The company is distinguished by its expertise in complex generics and its integrated approach to drug discovery and formulation development. Glenmark utilizes a network of advanced manufacturing facilities to deliver high-quality healthcare solutions globally, emphasizing innovation and accessibility in its product portfolio.

Recent filings

Filing Released Lang Actions
Press Release
Regulatory Filings Classification · 95% confidence The document is a press release announcing the launch of a new pharmaceutical product, GLIPIQ (Semaglutide), by Glenmark Pharmaceuticals. It includes details about the product, its pricing, formulation, and a patient support program. The document is addressed to stock exchanges and requests the announcement to be taken on record. There are no financial statements, regulatory filings, voting results, or management discussions present. The content is promotional and informational about a product launch rather than a financial or regulatory report. Therefore, it fits best under the category of a general regulatory announcement or miscellaneous filing that does not fit other specific categories.
2026-03-20 English
Press Release
Regulatory Filings Classification · 95% confidence The document is a press release announcing the launch of a new pharmaceutical product, GLIPIQ (Semaglutide), by Glenmark Pharmaceuticals. It includes details about the product, pricing, patient support programs, and company background. There are no financial statements, regulatory filings, voting results, or management changes. The document is a corporate announcement related to product launch and marketing, not a financial report or regulatory filing. Therefore, it does not fit into categories like Annual Report, Earnings Release, or Regulatory Filings. The closest fitting category is Regulatory Filings (RNS) as a general announcement to the stock exchanges and public about a significant corporate event that does not fall under other specific categories.
2026-03-20 English
Press Release
Capital/Financing Update Classification · 60% confidence The document is a formal announcement from Glenmark Pharmaceuticals Limited to stock exchanges regarding the launch of an authorized generic drug product. It includes a media release describing the product launch, market data, and company background. There are no financial statements, regulatory certifications, voting results, or management changes. The content is a corporate news announcement about a product launch, not a financial report, regulatory filing, or meeting material. It does not fit into categories like Annual Report, Earnings Release, or Regulatory Filings. The best fitting category is Capital/Financing Update (CAP) since it relates to a significant business development impacting the company's product portfolio and market presence, which can influence capital markets. However, since it is primarily a product launch announcement without direct financing or capital structure changes, the confidence is moderate.
2026-03-19 English
Press Release
Regulatory Filings Classification · 95% confidence The document is a formal announcement addressed to stock exchanges (BSE and NSE) regarding the launch of a new pharmaceutical product by Glenmark Therapeutics Inc., USA. It mentions FDA approval and provides details about the product and market context. The document includes a media release and contact information but does not contain any financial statements, detailed financial analysis, or regulatory filings such as annual or quarterly reports. It is a corporate announcement about a product launch rather than a financial report or regulatory filing. The length is about 5500 characters, which is consistent with a detailed announcement but not a full report. Therefore, this document fits best into the category of Regulatory Filings (RNS) as a general corporate announcement that does not fit into more specific categories like earnings release or capital update.
2026-03-19 English
Press Release
Regulatory Filings Classification · 95% confidence The document is a formal announcement from Glenmark Pharmaceuticals regarding the upcoming launch of a new pharmaceutical product, Potassium Phosphates Injection USP, with detailed product specifications and market context. It includes a media release and contact information for further inquiries. There are no financial statements, regulatory certifications, voting results, or management discussions present. The document is primarily an announcement of a product launch, not a financial report, regulatory filing, or management update. Therefore, it fits best under the category of a general regulatory announcement or miscellaneous corporate announcement that does not fit other specific categories. Given the nature and content, the most appropriate classification is Regulatory Filings (RNS).
2026-03-16 English
Press Release
Regulatory Filings Classification · 95% confidence The document is a formal announcement from Glenmark Pharmaceuticals Limited regarding the receipt of U.S. FDA approval for a specific pharmaceutical product, Fluticasone Propionate Inhalation Aerosol USP, 44 mcg per actuation. It includes details about the approval, the competitive generic therapy exclusivity, market data, and a statement from a company executive. There are no financial statements, quarterly or annual results, or detailed financial analysis present. The document is a regulatory announcement informing stock exchanges and the public about a significant product approval event. It does not fit into categories like Annual Report, Earnings Release, or Management Reports. It is not a report publication announcement since it is not announcing the release of a report but rather a corporate event. The best fitting category is Regulatory Filings (RNS), which covers general regulatory announcements and compliance-related disclosures that do not fit other specific categories.
2026-03-04 English

Browse filings by year

17 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.